Market revenue in 2024 | USD 11,085.5 million |
Market revenue in 2030 | USD 17,363.5 million |
Growth rate | 7.8% (CAGR from 2025 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | PAREXEL, Pharmaceutical Product Development, Charles River Laboratories International Inc, Icon PLC, SGS AG, Eli Lilly and Co, Pfizer Inc, Novo Nordisk A/S ADR, Labcorp Drug Development, Rebus Biosystems |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to omics-based clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 58.73% in 2024. Horizon Databook has segmented the U.S. omics-based clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. omics-based clinical trials market, including forecasts for subscribers. This country databook contains high-level insights into U.S. omics-based clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account